RECHERCHE :   Cancers urologiques
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
MK3475-676: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction
High risk bladder cancer
III
HUG
BMS CA022-001: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
Tumeurs solides avancées
I, II
CHUV
CA027-002: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers
Tumeurs solides avancés
I, II
CHUV
DZB-CS-201: An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)
cancer urothélial avancé présentant des aberrations génétiques de FGFR
I, II
CHUV
IMMU-132-13: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
Metastatic or Locally Advanced Unresectable Urothelial Cancer
III
HUG
MK6482-011: An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy
Advanced Renal Cell Carcinoma
III
HUG
CHUV-DO-0018-NeoTIL-2019: Pilot Study to Assess the Feasibility, Safety and Efficacy of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes Enriched for Tumor Antigen Specificity (NeoTIL) in Advanced Solid Tumors.
Tumeurs solides
I
CHUV
PSMAddition: an international prospective open-label, randomised, phase III study comparing 177Lu-PSMA-617 in ccmbination with standard of care, versus standard of care alone, in adult male patients with metastatic hormone sensitive prostate cancer (mHSPC)
cancer de la prostate métastatique hormonosensible (CPMHS)
III
CHUV
PSMAfore: a phase III, Open-label, Multi-center, Randomised study comparing 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
cancer métastatique de la prostate résistant à la castration
III
CHUV
SAKK 96/12: Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks – A Non-Inferiority Phase III Trial
Métastases osseuses dans le cancer de la prostate ou du sein
III
CHUV, HUG
SAKK06/19: Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC). A multicenter, single-arm phase II trial
muscle-invasive bladder cancer
II
HUG